FDA Approves Eflornithine for Children, Adults With High-Risk Neuroblastoma
December 14th 2023Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.
Pirtobrutinib Generates Durable Responses in CLL/SLL After BTKi Therapy
December 11th 2023The use of pirtobrutinib following covalent Bruton tyrosine kinase inhibitor therapy may be an important sequencing approach in chronic lymphocytic leukemia/small lymphocytic lymphoma, according to recent research.
Remote Monitoring May Reduce Inpatient Admission Rates Among Patients Receiving CAR T-Cell Therapy
December 10th 2023Remote patient monitoring following CAR T-cell therapy may reduce costs while allowing nurses to maintain a close eye on patient parameters, although more research is needed to refine the process of alerting virtual nurses of potential issues.
Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC
December 10th 2023The 5-year event-free survival rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab, compared with 72.3% in those who received placebo/chemotherapy plus placebo.
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
December 7th 2023The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.